SER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Serina Therapeutics Inc (SER) is not a strong buy for a beginner investor with a long-term strategy at this time. The company shows significant financial challenges, insider selling, and lacks clear positive trading signals. While the FDA clearance and private placement funding are positive, the financial performance and technical indicators do not suggest a strong entry point.
The MACD is above 0 and positively contracting, which is a mild bullish signal. RSI is neutral at 57.295, indicating no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. Key resistance levels are at 3.023 and 3.512, while support levels are at 1.442 and 0.953. The stock has a 50% chance of declining in the next day (-0.73%), week (-2.7%), and month (-0.89%).
FDA clearance for SER-252 and private placement funding of up to $30 million. Revenue increased by 116.7% YoY in FY 2025.
Gross margin dropped to 0, and EPS remains negative at -0.34.
In 2025/Q4, revenue was flat at $0, with no YoY growth. Net income improved by 31.02% YoY to -$3.59 million, but it remains negative. EPS increased by 13.33% YoY to -0.34, but gross margin dropped to 0, reflecting poor profitability.
No analyst rating or price target changes available for SER.
